ATC Group: N06DA03 Rivastigmine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06DA03 in the ATC hierarchy

Level	Code	Title
`1`	N	Nervous system
`2`	N06	Psychoanaleptics
`3`	N06D	Anti-dementia drugs
`4`	N06DA	Anticholinesterases
`5`	N06DA03	Rivastigmine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	9 mg
T-DERMAL	Transdermal	9.5 mg

Active ingredients in N06DA03

Active Ingredient
Rivastigmine
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer’s disease and Parkinson’s disease.

Related product monographs

Document	Type	Information Source
EXELON Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)
EXELON Transdermal patch	MPI, EU: SmPC	European Medicines Agency (EU)
NIMVASTID Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)